Cover Image
市場調查報告書

青光眼:美國的醫藥品市場預測與分析

Glaucoma - US Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 371771
出版日期 內容資訊 英文 241 Pages
訂單完成後即時交付
價格
Back to Top
青光眼:美國的醫藥品市場預測與分析 Glaucoma - US Drug Forecast and Market Analysis to 2023
出版日期: 2015年05月11日 內容資訊: 英文 241 Pages
簡介

本報告提供美國的青光眼治療藥臨床實驗趨勢與上市預測相關分析,提供您青光眼概要和症狀·原因,目前主要的治療方法,目前臨床實驗中的開發中產品概要 (功效,SWOT分析及其它),市場規模預測 (今後11年份),主要的推動市場要素與其影響度等調查評估。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告

第3章 疾病概要

  • 病因與病情
  • 分類
  • 症狀
  • 預後

第4章 疾病管理

  • 診斷·治療方法概要
    • 診斷
    • 治療指南
    • 主要的處方藥
    • 臨床評估
  • 美國

第5章 競爭產品的評估

  • 概要
  • 產品簡介:領導品牌和藥物類別

第6章 未滿足需求與市場機會

  • 概要
  • 給藥計劃的簡單化
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 注意提醒系統
  • 長期持續型的治療方法
  • 新級的降眼壓 (IOP) 藥
  • 神經保護藥
  • 診斷·監測手法的改良

第7章 開發中產品的評估

  • 概要
  • 臨床實驗
    • 臨床實驗製圖
    • 臨床實驗的設計
  • 臨床實驗階段有潛力的醫藥品
  • 臨床實驗的初期階段有潛力的醫藥品
  • 處於開發階段的其他醫藥品

第8章 市場未來展望

  • 美國
    • 預測
    • 近幾年主要的事件
    • 市場促進·阻礙因素

第9章 附錄

圖表一覽

目錄
Product Code: GDHC320CFR

Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie's Rhopressa, Bausch & Lomb's Vesneo (latanoprost bunod), and Inotek's trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market.

GlobalData estimates that drug sales for glaucoma in the US during 2013 reached $1.7 billion, making this the largest market within the 7MM. After an initial period of minimal growth, GlobalData estimates that the glaucoma market will follow a steady growth trend from 2018 onwards. This growth is mainly attributed to the expected introduction of five pipeline products during the forecast period, and the overall increase in prevalent cases of glaucoma that is mostly due to an aging society in the US.

Scope

  • Overview of Glaucoma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US Glaucoma market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Glaucoma.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in the US.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs
    • 4.1.4. Clinical Practice
  • 4.2. US

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Main Brands and Drug Classes
    • 5.2.1. Xalatan (latanoprost)
    • 5.2.2. Lumigan (bimatoprost)
    • 5.2.3. Travatan (travoprost)
    • 5.2.4. Tapros (tafluprost)
    • 5.2.5. Beta Blockers
    • 5.2.6. Carbonic Anhydrase Inhibitors
    • 5.2.7. Alpha-Adrenergic Agonists
    • 5.2.8. Simbrinza (brinzolamide + brimonidine)
    • 5.2.9. Glanatec (ripasudil hydrochloride hydrate)

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Simplified Dosing Regimen
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Reminder Systems
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Long-Acting Therapy
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. New Classes of IOP-Lowering Drugs
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Neuroprotective Drugs
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improved Diagnosis and Monitoring
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trials
    • 7.2.1. Clinical Trial Mapping
    • 7.2.2. Clinical Trial Design
  • 7.3. Promising Drugs in Clinical Development
    • 7.3.1. Rhopressa
    • 7.3.2. Roclatan
    • 7.3.3. Vesneo
    • 7.3.4. Bimatoprost SR
    • 7.3.5. Trabodenoson
    • 7.3.6. OPC-1085EL
    • 7.3.7. DE-117
    • 7.3.8. OXT-TP
  • 7.4. Promising Drugs in Early-Stage Development
    • 7.4.1. ROCK Inhibitor AMA-0076
    • 7.4.2. Sustained-Release PGA Products
  • 7.5. Other Drugs in Development

8. Market Outlook

  • 8.1. US
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Percent Drug-Treated Patients
    • 9.4.2. Drugs Included in Each Therapeutic Class
    • 9.4.3. Launch and Patent Expiry Dates
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - High-prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Glaucoma
  • Table 2: Diagnostic Tests for Glaucoma.
  • Table 3: National and International Treatment Guidelines for Glaucoma
  • Table 4: Most Prescribed Drugs for Glaucoma in the Global Markets, 2013
  • Table 5: Country Profile - US
  • Table 6: Leading Treatments for Glaucoma, 2013
  • Table 7: Product Profile - Xalatan
  • Table 8: Xalatan SWOT Analysis, 2014
  • Table 9: Global Sales Forecast ($m) for Xalatan, 2013-2023
  • Table 10: Global Sales Forecast ($m) for Generic Latanoprost, 2013-2023
  • Table 11: Product Profile - Lumigan
  • Table 12: Lumigan SWOT Analysis, 2014
  • Table 13: Global Sales Forecast ($m) for Lumigan, 2013-2023
  • Table 14: Product Profile - Travatan
  • Table 15: Travatan SWOT Analysis, 2014
  • Table 16: Global Sales Forecast ($m) for Travatan/Travatan Z, 2013-2023
  • Table 17: Global Overview of Tafluprost
  • Table 18: Product Profile - Tapros Franchise
  • Table 19: Tafluprost Adverse Events
  • Table 20: Tafluprost SWOT Analysis, 2014
  • Table 21: Global Sales Forecast ($m) for the Tapros Franchise, 2013-2023
  • Table 22: Beta Blockers Available in the 7MM
  • Table 23: Global Sales Forecast ($m) for Beta Blocker Drugs, 2013-2023
  • Table 24: Carbonic Anhydrase Inhibitors Available in the 7MM
  • Table 25: Global Sales Forecast ($m) for Carbonic Anhydrase Inhibitor Drugs, 2013-2023
  • Table 26: Alpha-Adrenergic Agonists available in the 7MM
  • Table 27: Global Sales Forecast ($m) for Alpha-Adrenergic Agonist Drugs, 2013-2023
  • Table 28: Product Profile - Simbrinza
  • Table 29: Simbrinza SWOT Analysis, 2014
  • Table 30: Global Sales Forecast ($m) for Simbrinza, 2013-2023
  • Table 31: Product Profile - Glanatec
  • Table 32: Glanatec SWOT Analysis, 2014
  • Table 33: Global Sales Forecast ($m) for Glanatec, 2013-2023
  • Table 34: Unmet Needs and Opportunities in Glaucoma
  • Table 35: Promising Drugs in Clinical Development for Glaucoma
  • Table 36: Comparison of Drugs in Development for Glaucoma, 2014
  • Table 37: Product Profile - Rhopressa
  • Table 38: SWOT Analysis - Rhopressa, 2014
  • Table 39: Global Sales Forecasts ($m) for Rhopressa, 2013-2023
  • Table 40: Product Profile - Roclatan
  • Table 41: SWOT Analysis - Roclatan, 2014
  • Table 42: Global Sales Forecasts ($m) for Roclatan, 2013-2023
  • Table 43: Product Profile - Vesneo
  • Table 44: SWOT Analysis - Vesneo, 2014
  • Table 45: Global Sales Forecasts ($m) for Vesneo, 2013-2023
  • Table 46: Product Profile - Bimatoprost SR
  • Table 47: SWOT Analysis - Bimatoprost SR, 2014
  • Table 48: Global Sales Forecasts ($m) for Bimatoprost SR, 2013-2023
  • Table 49: Product Profile - Trabodenosen
  • Table 50: SWOT Analysis - Trabodenoson, 2014
  • Table 51: Global Sales Forecasts ($m) for Trabodenosen, 2013-2023
  • Table 52: Product Profile - OPC-1085EL
  • Table 53: SWOT Analysis - OPC-1085EL, 2014
  • Table 54: Global Sales Forecasts ($m) for OPC-1085EL, 2013-2023
  • Table 55: Product Profile - DE-117
  • Table 56: SWOT Analysis - DE-117, 2014
  • Table 57: Product Profile - OXT-TP
  • Table 58: SWOT Analysis - OTX-TP, 2014
  • Table 59: Drugs in Development, 2014
  • Table 60: US Sales Forecast ($m) for Glaucoma, 2013-2023
  • Table 61: Key Events Impacting Sales for Glaucoma in the US, 2013-2023
  • Table 62: Glaucoma Market - Drivers and Barriers in the US, 2013-2023
  • Table 63: Key Launch Dates
  • Table 64: Key Patent Expiries
  • Table 65: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Open and Closed Iridocorneal Angles
  • Figure 2: The Aqueous Humor Cycle
  • Figure 3: Optic Nerve Damage - Cupping
  • Figure 4: Comparison of Healthy and Glaucomous Optic Nerves
  • Figure 5: Glaucoma Clinical Treatment Flowchart
  • Figure 6: Glaucoma - Number of Phase II and III/IIb Clinical Trials in Various Drug Classes in the 7MM
  • Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in Glaucoma, 2013-2023
  • Figure 8: Rhopressa's Development in Glaucoma
  • Figure 9: Clinical and Commercial Positioning of Rhopressa
  • Figure 10: Roclatan's Development in Glaucoma
  • Figure 11: Clinical and Commercial Positioning of Roclatan
  • Figure 12: Vesneo Development in Glaucoma
  • Figure 13: Clinical and Commercial Positioning of Vesneo
  • Figure 14: Clinical and Commercial Positioning of Bimatoprost SR
  • Figure 15: Trabodenoson's Development in Glaucoma
  • Figure 16: Clinical and Commercial Positioning of Trabodenosen
  • Figure 17: OPC-1085EL's Development in Glaucoma
  • Figure 18: Clinical and Commercial Positioning of OPC-1085EL
  • Figure 19: DE-117's Development in Glaucoma
  • Figure 20: Drug Sales by Class for Glaucoma in the US, 2013-2023
Back to Top